Ventricular Tachycardia:A Registry Study
A legfontosabb adatok
- Ki végzi
- Beijing Anzhen Hospital
- Hol
- Beijing (Kína)A helyszín megnézése
- Azonosító
- Állapot
- Toboroz
- Résztvevők
- 1000 fő, tervezett
- Kezdés
- 2025. okt. 14.
- Várható befejezés
- 2029. dec. 1.
- A vizsgálat típusa
- Megfigyeléses
- A vizsgált kezelések
- Standard Clinical Care
- A regiszteradat frissítve
- 2026. július 29.
Ki vehet részt
MI-összefoglaló
A vizsgálat saját részvételi feltételeiből. Gép olvasta ki az oldalon álló regiszterszövegből, ezért tévedhet. Hogy ki vehet részt, azt a lenti regiszterszöveg és a vizsgálat csapata dönti el.
The trial is looking for adults with structural heart disease and a fast abnormal heart rhythm from the lower heart chambers (ventricular tachycardia). It only observes their usual care.
- Életkor
- 18 years and older
- Nem
- All sexes
- A betegség stádiuma
- Sustained ventricular tachycardia, or short episodes (nonsustained) that the doctor thinks need treatment. It must be confirmed by a heart recording or heart test. Structural heart disease must be diagnosed under current guidelines.
- Korábbi kezelés
- No heart surgery in the 60 days before joining.
A részvétel fő kizáró okai
- Ventricular tachycardia from a reversible cause, such as acute lack of blood flow to the heart or salt imbalances in the blood
- Ventricular tachycardia with no sign of structural heart disease
- Severe infection, such as sepsis or septic shock
- Severe bleeding or clotting problems, including platelet count <50 × 10⁹/L or disseminated intravascular coagulation
- Taking part in another treatment study that may interfere with this registry
A regiszter feltételei, szó szerint
Mind a 12 feltétel megnézéseKevesebb
Ki vehet részt
- Adults aged ≥18 years
- Documented sustained ventricular tachycardia (VT), or nonsustained VT requiring therapeutic intervention in the investigator's judgment, confirmed by a 12-lead electrocardiogram, ambulatory electrocardiographic monitoring, continuous cardiac monitoring, implantable cardiac device recordings, or electrophysiological study
- Structural heart disease diagnosed according to current clinical guidelines
- Willing and able to provide written informed consent
- Willing to comply with the study follow-up schedule
Ki nem vehet részt
- Cardiac surgery within 60 days before enrollment
- Ventricular tachycardia secondary to reversible causes (e.g., acute myocardial ischemia or electrolyte disturbances)
- Idiopathic ventricular tachycardia without evidence of structural heart disease
- Severe infectious diseases (e.g., septic shock or sepsis)
- Any other condition that, in the investigator's judgment, makes the participant unsuitable for study participation
- Severe coagulation disorders, including platelet count <50 × 10⁹/L or disseminated intravascular coagulation
- Participation in another interventional clinical study that may interfere with this registry
Helyszínek itt: Kína
- Beijing Anzhen Hospital, Capital Medical UniversityBeijing, KínaContact: Deyong Long, MDRésztvevőt keres
A vizsgálatról
Mit akar kideríteni a vizsgálat
Structural heart disease-related ventricular tachycardia (SHD-VT) is associated with substantial morbidity and mortality. Although catheter ablation, ICD therapy, antiarrhythmic drugs, and other treatment strategies are widely used, real-world evidence regarding patient characteristics, management patterns, long-term outcomes, and prognostic factors in China remains limited. This nationwide, multicenter, prospective observational registry aims to establish a comprehensive longitudinal database of patients with SHD-VT. Approximately 1,000 consecutive adult patients with documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, in the presence of structural heart disease will be enrolled and followed prospectively. The study will collect detailed demographic characteristics, medical history, imaging findings, laboratory data, electrophysiological characteristics, treatment strategies, and follow-up outcomes without influencing routine clinical management. The primary effectiveness outcome is a composite of ventricular tachycardia recurrence or appropriate ICD therapy (when applicable), unplanned cardiovascular hospitalization, or all-cause death within 12 months. Long-term follow-up will continue to evaluate clinical outcomes, treatment safety, and prognostic factors. The registry is expected to provide high-quality real-world evidence to improve risk stratification, optimize clinical decision-making, and support future clinical research in patients with SHD-VT.
A vizsgálat csoportja
- SHD-VT Cohort
This cohort includes consecutive adult patients with structural heart disease and documented sustained ventricular tachycardia, or clinically significant nonsustained ventricular tachycardia requiring treatment, enrolled in a prospective multicenter observational registry. All treatment decisions are made according to routine clinical practice without study intervention.
Kezelés: Standard Clinical Care
Kérdések a vizsgálat csapatának
- Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
- Megtérítik az utazási költséget?
- Megtarthatom a saját orvosomat?
- Mi történik, ha ki akarok lépni?
Contact the study team: see the registry record → Contacts and Locations
Oldal nyomtatása az orvosomnakAdatok és források
- Regiszteradat
- Szerepel a ClinicalTrials.gov-on.
- MI-összefoglaló
- A vizsgálat saját részvételi feltételeiből. Gépi kiolvasás: 2026. november 14.
- A regiszteradat frissítve
- 2026. július 29.